Acivir DT — Research Summary
Acivir DT 400 mg is an antiviral research compound containing acyclovir as the active pharmaceutical ingredient, manufactured by Cipla in dispersible tablet formulation. Acyclovir is a synthetic purine nucleoside analogue that researchers investigate for its selective inhibition of viral DNA polymerase enzymes in laboratory studies. The dispersible tablet format enables researchers at Stroid UK Shop to examine dissolution characteristics and bioavailability parameters in controlled experimental conditions. This pharmaceutical-grade compound serves as a reference standard for antiviral mechanism studies, particularly in examining herpesvirus DNA replication pathways and nucleoside analogue pharmacokinetics in cellular models.
Research Applications
Laboratory investigations utilise Acivir DT 400 mg to examine antiviral mechanisms through selective viral DNA polymerase inhibition studies. Researchers analyse how acyclovir undergoes phosphorylation by viral thymidine kinase, creating active triphosphate metabolites that interfere with viral DNA synthesis processes. The dispersible formulation allows scientists to investigate drug dissolution profiles, absorption kinetics, and cellular uptake mechanisms in various experimental models. Studies within the broader antiviral research category examine structure-activity relationships between nucleoside analogues and their inhibitory effects on viral replication machinery. Comparative investigations assess acyclovir’s selectivity profile against viral versus cellular DNA polymerases, providing insights into therapeutic index mechanisms.
Technical Specifications
| Active Ingredient | Acyclovir |
|---|---|
| Strength | 400 mg per tablet |
| Formulation | Dispersible tablets |
| Manufacturer | Cipla Limited |
| CAS Number | 59277-89-3 |
| Molecular Formula | C₈H₁₁N₅O₃ |
| Molecular Weight | 225.20 g/mol |
| Storage | Room temperature, dry conditions |
Unlike compounds studied in selective androgen receptor modulator research or peptide investigations, acyclovir functions through nucleoside analogue mechanisms targeting viral DNA replication enzymes specifically.
Research Compliance
Acivir DT 400 mg is supplied strictly for in-vitro laboratory research applications only. This compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must handle this material according to standard laboratory safety protocols and institutional guidelines for pharmaceutical research compounds. All investigations must comply with relevant research regulations and institutional review board requirements for antiviral mechanism studies.
